NCT04283552

Brief Summary

The goal of this study is to see how the images collected during the first hour compare with the routine images collected as part of the clinical scan.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 20, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 25, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

May 29, 2020

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 10, 2023

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

May 20, 2024

Completed
Last Updated

May 20, 2024

Status Verified

May 1, 2024

Enrollment Period

2.9 years

First QC Date

February 20, 2020

Results QC Date

April 9, 2024

Last Update Submit

May 13, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Feasibility of Rapid, Whole-body Dynamic PET Imaging as Measured by Number of Participants Who Successfully Completed the Study Imaging Component

    -Successful completion of the study imaging component will be defined as: (1) patient remains on scanner for the full dynamic phase of PET imaging prior to the standard of care PET/CT and (2) automated scanner software is able to successfully generate valid parametric maps (requires at least three consecutive whole-body PET acquisitions without substantial motion between acquisitions).

    At time of scan (day 1)

Secondary Outcomes (11)

  • Quantitative Impacts of Data Motion Correction (OncoFreeze) as Measured by Semi-quantitative Standardized Uptake Value (SUV)-Max

    At the time of scan (Day 1)

  • Quantitative Impacts of Data Motion Correction (OncoFreeze) as Measured by Lesion Contrast-to-noise Ratios (CNRs)

    At the time of scan (Day 1)

  • Clinical Impacts of Data Motion Correction (OncoFreeze) as Measured by Mean Relative Lesion Number Between Ungated and Belt-gating Optimal Gate

    At the time of scan (Day 1)

  • Clinical Impacts of Data Motion Correction (OncoFreeze) as Measured by Mean Relative Lesion Number Between Ungated and Elastic Motion Correction With Blurring Utilizing Belt Gating

    At the time of scan (Day 1)

  • Clinical Impacts of Data Motion Correction (OncoFreeze) as Measured by Mean Relative Lesion Number Between Ungated and Elastic Motion Correction With Blurring Utilizing Data-driven Gating

    At the time of scan (Day 1)

  • +6 more secondary outcomes

Study Arms (1)

Dynamic PET Imaging

EXPERIMENTAL

* Dynamic PET/CT imaging will begin at approximately the same time as the clinically prescribed radiotracer injection and will continue until approximately the start of the clinical scan * A subset of patients (up to 30 scheduled to undergo FDG or DOTATATE PET/CT imaging) will be asked to return within 7 days for a repeat imaging study.

Device: Dynamic PET/CT Imaging

Interventions

-Will take approximately 60 minutes

Dynamic PET Imaging

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older
  • Scheduled to undergo a clinical PET/CT scan with any clinically prescribed radiotracer for known or suspected malignancy (pathologic confirmation not required)
  • Able to provide informed consent
  • years of age or older
  • Scheduled to undergo a clinical PET/CT FDG or 68Ga- DOTA-0-Tyr3-Octreotate (DOTATATE) for known or suspected malignancy (pathologic confirmation not required)
  • Able to provide informed consent

You may not qualify if:

  • Younger than 18 years of age

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location

Related Links

Results Point of Contact

Title
Richard L. Wahl, M.D.
Organization
Washington University School of Medicine

Study Officials

  • Richard L Wahl, M.D.

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 20, 2020

First Posted

February 25, 2020

Study Start

May 29, 2020

Primary Completion

April 10, 2023

Study Completion

April 10, 2023

Last Updated

May 20, 2024

Results First Posted

May 20, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will share

The investigators may share your images with other researchers. They may be doing research in areas similar to this research or in other unrelated areas. These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research. The investigators may also share your research data with large data repositories (a repository is a database of information) for broad sharing with the research community. If the individual research data is placed in one of these repositories only qualified researchers, who have received prior approval from individuals that monitor the use of the data, will be able to look at the information.

Shared Documents
STUDY PROTOCOL, ICF, CSR
Time Frame
Beginning 3 months and ending 10 years following article publication.
Access Criteria
Proposals should be directly submitted to rwahl@wustl.edu.

Locations